ANVS/ 07/07/2026 · 4:56 PM Annovis Bio Gets Bullish Coverage from Roth Capital Amid Phase 3 Momentum Annovis Bio receives bullish coverage from Roth Capital as its Phase 3 Alzheimer’s trial hits full enrollment.
